Bristol-myers Squibb Compnay

Qi Chen

Makonen Belema

Omar D Lopez

John A Bender

Gan Wang

Nicholas A Meanwell

Piyasena Hewawasam

Van N Nguyen

Zhong Yang

John F Kadow

Lawrence G Hamann

Edward H Ruediger

Jeffrey Lee Romine

Denis R St Laurent

Carol Bachand

Rico Lavoie

Ningning Xu

Michael J Smith

John A Easter

Bao-Ning Su

The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

Hepatitis C virus inhibitors

This disclosure concerns novel compounds of Formula (I) as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds.

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

Growing community of inventors

Stamford, CT, United States of America

Qi Chen